|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.85 USD | -1.64% |
|
-1.88% | +0.91% |
| 05-12 | Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley | MT |
| 05-12 | Morgan Stanley Cuts Price Target on Halozyme Therapeutics to $93 From $96, Keeps Overweight Rating | MT |
| Capitalization | 8.18B 7.04B 6.44B 6.09B 11.24B 790B 11.43B 76.35B 29.88B 373B 30.7B 30.05B 1,299B | P/E ratio 2026 * |
10.2x | P/E ratio 2027 * | 7.9x |
|---|---|---|---|---|---|
| Enterprise value | 9.4B 8.08B 7.4B 6.99B 12.92B 908B 13.13B 87.72B 34.33B 429B 35.27B 34.53B 1,493B | EV / Sales 2026 * |
5.29x | EV / Sales 2027 * | 4.12x |
| Free-Float |
98.94% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Halozyme Therapeutics, Inc.
| 1 day | -1.15% | ||
| 1 week | -2.33% | ||
| Current month | +6.19% | ||
| 1 month | -1.18% | ||
| 3 months | -4.30% | ||
| 6 months | -3.90% | ||
| Current year | +0.45% |
| 1 week | 66.3 |  | 69.74 |
| 1 month | 62.38 | | 73.89 |
| Current year | 61.32 | | 82.22 |
| 1 year | 51.06 | | 82.22 |
| 3 years | 31.86 | | 82.22 |
| 5 years | 29.85 | | 82.22 |
| 10 years | 7.7 | | 82.22 |
| Manager | Title | Age | Since |
|---|---|---|---|
Helen Torley
CEO | Chief Executive Officer | 63 | 06/01/2014 |
David Ramsay
DFI | Director of Finance/CFO | 61 | 01/05/2013 |
Charles Theuer
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Matthew Posard
BRD | Director/Board Member | 58 | 28/03/2013 |
Helen Torley
BRD | Director/Board Member | 63 | 06/01/2014 |
| Chairman | 61 | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.20% | -2.33% | +25.35% | +93.14% | 8.18B | |
| +2.81% | +4.43% | +7.09% | -24.08% | 62.06B | |
| +0.93% | +1.57% | +7.48% | -12.79% | 7.84B | |
| -2.15% | -8.27% | +2.02% | +27.99% | 4.76B | |
| +0.25% | -3.78% | -22.75% | +48.31% | 4.04B | |
| +0.25% | -4.68% | -2.09% | -27.47% | 3.02B | |
| -0.84% | -5.28% | +48.62% | +40.48% | 2.83B | |
| -1.93% | -4.01% | +16.09% | -10.48% | 2.37B | |
| -0.27% | -6.48% | +65.26% | +24.82% | 1.89B | |
| -6.72% | -11.23% | +36.62% | -3.88% | 1.74B | |
| Average | -0.86% | -4.45% | +18.37% | +15.61% | 9.87B | |
| Weighted average by Cap. | +1.47% | -0.78% | +9.92% | -4.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.78B 1.53B 1.4B 1.32B 2.44B 172B 2.48B 16.58B 6.49B 81.02B 6.67B 6.53B 282B | 2B 1.72B 1.57B 1.49B 2.75B 193B 2.79B 18.65B 7.3B 91.14B 7.5B 7.34B 317B |
| Net income | 821M 706M 647M 611M 1.13B 79.34B 1.15B 7.67B 3B 37.45B 3.08B 3.02B 130B | 1.04B 898M 822M 777M 1.44B 101B 1.46B 9.75B 3.81B 47.62B 3.92B 3.84B 166B |
| Net Debt | 1.22B 1.05B 959M 906M 1.67B 118B 1.7B 11.37B 4.45B 55.53B 4.57B 4.47B 193B | 53.58M 46.08M 42.18M 39.85M 73.64M 5.18B 74.82M 500M 196M 2.44B 201M 197M 8.51B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/05/26 | 67.92 $ | -1.54% | 168,638 |
| 20/05/26 | 68.98 $ | +0.36% | 1,426,428 |
| 19/05/26 | 68.73 $ | +1.91% | 2,004,305 |
| 18/05/26 | 67.44 $ | +0.48% | 1,780,901 |
| 15/05/26 | 67.12 $ | -3.02% | 2,144,688 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HALO Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition